XML 46 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
NewLink Merger - Narrative (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 19, 2020
Mar. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Mar. 18, 2020
USD ($)
director
Business Acquisition [Line Items]          
Number of directors | director         3
In-process research and development charge     $ 0 $ 426  
Private Lumos Stockholders          
Business Acquisition [Line Items]          
Number of directors | director         3
Private Lumos Stockholders | NewLink Genetics          
Business Acquisition [Line Items]          
Ownership percentage after transaction 0.50        
Merck | License and Collaborative Arrangement          
Business Acquisition [Line Items]          
Estimated transaction price         $ 95,000
Economic interest in PRV         87,900
PRV-related liability owed to Merck         35,700
Step up in basis in the PRV         9,500
In-process research and development charge   $ 426      
Merck | License and Collaborative Arrangement | Minimum          
Business Acquisition [Line Items]          
Observed transaction price         80,000
Merck | License and Collaborative Arrangement | Maximum          
Business Acquisition [Line Items]          
Observed transaction price         $ 111,000